An HDAC6/JAK2 inhibitor was designed based on vorinostat and pacritinib, and showed preclinical efficacy in AML and ALL.694 CUDC-907, an HDAC/PI3K inhibitor, exerted an ORR of 37% in R/R DLBCL patients, including those with MYC-alterations.695 HDAC/LSD1 inhibitors and HDAC I/tubulin inhibitors display favorable efficacy in solid tumors, such as colon cancer and breast cancer, but few studies have explored their application to hematologic malignancies.696,697. This evidence concerns the gene MYC and hematologic disorder.